2633 — Jacobson Pharma Income Statement
0.000.00%
Last trade - 00:00- HK$2.70bn
- HK$3.23bn
- HK$1.58bn
- 94
- 83
- 55
- 93
Annual income statement for Jacobson Pharma, fiscal year end - March 31st, HKD millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | R2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1,446 | 1,596 | 1,268 | 1,468 | 1,577 |
| Cost of Revenue | |||||
| Gross Profit | 561 | 621 | 539 | 620 | 693 |
| Selling / General / Administrative Expenses | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1,190 | 1,335 | 954 | 1,135 | 1,162 |
| Operating Profit | 256 | 261 | 313 | 333 | 415 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 221 | 231 | 250 | 255 | 374 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 186 | 188 | 207 | 210 | 301 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | 174 | 178 | 251 | 267 | 301 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 174 | 178 | 251 | 267 | 301 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.065 | 0.094 | 0.097 | 0.109 | 0.153 |
| Dividends per Share | |||||
| Special Dividends per Share |